CorMedix Inc.

Day range

$7.76 – $8.09

Open

$8.06

Prev close

$7.85

Volume

817.17K

Market cap

$611.86M

Shares out

77.94M

P/E

3.27

P/S

1.32

P/B

1.33

P/FCF

2.44

ROE

40.6%

ROA

20.7%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Regulatory decisionOct 19, 2026

  On October 19, 2026, CorMedix, Inc. issued a press release announcing that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) seeking approval of REZZAYO® (rezafungin for injection) for the prophylaxis of invasive fungal disease.

• Executive officer appointmentJul 2, 2026

  the Company's Board of Directors has appointed Elizabeth Hurlburt, currently the Chief Operating Officer, to the newly created role of Chief Operating and Commercial Officer where she will have functional oversight of all commercial functions in addition to medical affairs, regulatory and clinical.

• Internal control weaknessJul 1, 2026

  The material weakness in the Company's internal control over financial reporting as initially reported in Item 9A of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the Securities and Exchange Commission (the "SEC") on March 5, 2026, related to the operational effectiveness of an internal control to ensure adequate and timely review of significant, non-routine transactions.

• Charter amendmentJun 24, 2026

  Proposal No. 6 was to approve an amendment to the Company's Charter to update the approval process for amendments relating solely to the terms of one or more series of preferred stock by permitting such amendments to be approved by the holders of the applicable series, without a separate vote of common stockholders.

• Clinical trial resultsApr 27, 2026

  On April 27, 2026, CorMedix, Inc. (the "Company" or "CorMedix") issued a press release announcing an update related to the initial readout of topline data for the Phase III study (ReSPECT) assessing REZZAYO® (rezafungin for injection) for prophylaxis of invasive fungal infections.

Days to cover

18.9

Short interest

15.42M

Avg volume

815.97K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?
  positiveZacks Investment Research· Oct 8, 2026
• CorMedix Builds a Real Revenue Story as DefenCath Adoption Accelerates
  positiveInvesting.com· Dec 24, 2025
• American Kidney Fund Hosts Third Patient Access Initiative Summit to Address Barriers to Kidney Care and Propose Innovative Solutions
  neutralGlobeNewswire Inc.· Nov 21, 2025
• Strong Earnings and Biotech Resilience Define the Midweek Momentum
  positiveGlobeNewswire Inc.· Nov 12, 2025
• CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO
  positiveBenzinga· Sep 29, 2025